MỘT SỐ YẾU TỐ LIÊN QUAN ĐẾN SỬ DỤNG NHÓM THUỐC ỨC CHẾ SGLT-2 Ở BỆNH NHÂN SUY TIM PHÂN SUẤT TỐNG MÁU GIẢM NHẬP VIỆN TẠI BỆNH VIỆN ĐA KHOA TRUNG ƯƠNG CẦN THƠ NĂM 2024

Abstract

Background: Heart failure with reduced ejection fraction (HFrEF) accounts for approximately 50% of all heart failure cases worldwide. Although sodium-glucose cotransporter-2 inhibitors (SGLT-2i) are strongly recommended for the treatment of HFrEF, their utilization in Vietnam—particularly in Can Tho—remains limited. Objectives: To investigate factors associated with the use of SGLT-2 inhibitors among hospitalized patients with HFrEF at Can Tho City General Hospital in 2024. Materials and methods: A cross-sectional descriptive study was conducted on 106 patients with HFrEF admitted for treatment at Can Tho Central General Hospital. Results: The majority of patients were male (56.0%), with most aged between 60 and 79 years (62.9%). The mean NT-proBNP level and left ventricular ejection fraction (LVEF) were 7582 ± 8544 pg/mL and 35.6 ± 4.2%, respectively. In univariate analysis, female gender, overweight/obesity, type 2 diabetes mellitus, and the use of ARB/ACEI/ARNI or MRA were significantly associated with SGLT-2i use (p < 0.05). In multivariate analysis, female gender, comorbid type 2 diabetes, and atrial fibrillation were independently associated with SGLT-2i use (p < 0.05). Conclusion: Female gender, comorbid type 2 diabetes mellitus, and atrial fibrillation were independent factors associated with the use of SGLT-2 inhibitors in patients with HFrEF.